Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Natalie Gauld

Natalie Gauld

Dr Natalie Gauld is a pharmacist and reclassification consultant at Natalie Gauld Ltd. She is an Honorary Research Fellow at the Department of General Practice and Primary Health Care, University of Auckland, New Zealand. She has received funding for reclassifications including trimethoprim, vaccinations, calcipotriol, adapalene, sildenafil and oral contraceptives. She was on the Medicines Classification Committee in NZ (2004-2009). She has consulted to Green Cross Health, the pharmaceutical industry and pharmacy organisations. She has received travel funding for speaking engagements at conferences from industry and pharmacy organisations. She received unrestricted research grants from Green Cross Health, the Pharmacy Guild, the Pharmaceutical Society of NZ and ProPharma for the trimethoprim research. She is a member of the National Executive of the Pharmaceutical Society of NZ. The opinions expressed in this article are the author’s, and not as a representative of any organisation.

Recent stories

  • Illustration of over-the-counter products

    Why the resurgence of POM-to-P reclassifications in the UK is a good thingSubscription

    9 MAY 2017

    After a dwindle in the number of reclassifications of prescription-only to pharmacy medicines in the UK, things are starting to look up, writes Natalie Gauld.

  • Pharmacists in New Zealand can now prescribe the oral contraception pill to womenSubscription

    9 MAR 2017

    We have come a long way from the early days of the oral contraceptive pill, where the doctor would only prescribe it to women who were married, and then told them soon after that it was time to stop it and have babies. But in most countries we have not come far enough. The oral contraceptive is one of the safest and most well studied medicines available. However, aided by media sensationalism of adverse events, women worry about taking it for too long. They do not know that women who t

  • New Zealand first to have OTC topical adapalene available in pharmaciesSubscription

    26 SEP 2016

    In August 2016, pharmacists in New Zealeand were given permission to supply adapalene without a prescription through reclassification. This is in line with both Singapore (approval March 2016) and the United States (approval July 2016). For New Zealand and the United States, a major consideration was potential teratogenicity, with both countries considering non-prescription status was appropriate based on the evidence. Interestingly, Germany took a different approach, rejecting the ada

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.